Hyloris Pharmaceuticals SA

DB:52U Stock Report

Market Cap: €160.7m

Hyloris Pharmaceuticals Future Growth

Future criteria checks 2/6

Hyloris Pharmaceuticals's earnings are forecast to decline at 13.6% per annum while its annual revenue is expected to grow at 70.3% per year. EPS is expected to decline by 4.5% per annum.

Key information

-13.6%

Earnings growth rate

-4.5%

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth rate70.3%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:52U - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202633-19-45-192
12/31/202511-19-24-182
12/31/20247-16-15-152
6/30/20247-13-13-12N/A
3/31/20246-14-13-12N/A
12/31/20234-15-14-13N/A
9/30/20233-14-13-12N/A
6/30/20233-13-12-11N/A
3/31/20233-12-13-12N/A
12/31/20222-12-14-13N/A
9/30/20223-10-12-11N/A
6/30/20223-8-9-8N/A
3/31/20223-10-11-10N/A
12/31/20213-12-12-11N/A
9/30/20212-12-13-13N/A
6/30/20211-12-14-14N/A
3/31/20211-10-7-7N/A
12/31/20200-7-5-5N/A
9/30/20200-8-5-4N/A
6/30/20200-8-5-4N/A
3/31/20200-6-8-6N/A
12/31/20190-5-6-5N/A
12/31/20180-6-5-5N/A
12/31/20170-4N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 52U is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 52U is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 52U is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 52U's revenue (70.3% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 52U's revenue (70.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 52U's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y